|
Daehan Nupharm Launches Korea’s First Combination Therapy of Rabeprazole and Magnesium Oxide for GERD
2023.12.20
|
|---|
|
Daehan Nupharm announced that it has received marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its new gastroesophageal reflux disease (GERD) treatment, “Rapiduo Tab.” As part of its transformation into a research-driven pharmaceutical and biotech company, the firm is focusing on the development of both incremental and innovative new drugs. Rapiduo Tab is one of the company’s key pipeline products and represents a novel combination of rabeprazole (a proton pump inhibitor, PPI) and an antacid.
Rapiduo Tab demonstrated a Tmax of less than one hour after administration, confirming superior acid control versus reference products. It also applies dual-core tablet technology to reduce tablet size and improve patient compliance.
Rapiduo Tab 10/350 mg is scheduled for launch in March 2024, while the 20/350 mg high-dose formulation is planned for release in the second half of 2024. Daehan Nupharm continues to expand its incremental drug development efforts across both the gastroenterology and cardiovascular therapeutic areas. |


Home